PERSHING-SQUARE-HOLDINGS
Regulatory News:
Pershing Square Holdings, Ltd. (ticker: PSH:NA) today released the following regular monthly Net Asset Value (NAV) and Performance Report for the month of June 2015. The information has also been posted to the PSH website, www.pershingsquareholdings.com . Monthly net asset value and performance are calculated at the close of business on the last business day of the month.
|
PERSHING SQUARE CAPITAL MANAGEMENT, L.P. |
PERSHING SQUARE HOLDINGS, LTD. |
|||||||||||||||||
| Portfolio Update | ||||||||||||||||||
| June 30, 2015 | ||||||||||||||||||
| Summary Results | Number of Positions > 0.5% | |||||||||||||||||
| June | YTD 2015 | |||||||||||||||||
| Gross Performance | -3.8% | 4.6% | Long | 11 | ||||||||||||||
| Net Performance (1) | -3.4% | 3.2% | Short | 1 | ||||||||||||||
| NAV/Share | $27.23 | Total | 12 | |||||||||||||||
| Equity & Debt Exposure Composition By Market Cap (2) | Portfolio Composition by Sector (3) | |||||||||||||||||
| Net Portfolio | Long | Short | ||||||||||||||||
| Large Cap | 98% | 103% | -5% | Consumer Products | RE Corp. | |||||||||||||
| Mid Cap | 4% | 4% | 0% | Financials | Restaurant | |||||||||||||
| Small Cap | 0% | 0% | 0% | Healthcare | Transportation | |||||||||||||
| Total | 102% | 107% | -5% | Industrials/Chemicals | Undisclosed Position | |||||||||||||
| Note: Large Cap >= $5b; Mid Cap >= $1b; Small Cap < $1b | ||||||||||||||||||
| Assets Under Management | Notional Credit Default Swap Exposure | |||||||||||||||||
| Pershing Square Holdings, Ltd. AUM(4) | $ | 6,814.8M | Single Name & Sovereign CDS | $ | 44.6M | |||||||||||||
| Total Strategy AUM(5) | $ | 18,530.6M | ||||||||||||||||
| Total Firm AUM(6) | $ | 19,045.5M | Total CDS | $ | 44.6M | |||||||||||||
| PAST PERFORMANCE IS NOT NECESSARILY INDICATIVE OF FUTURE RESULTS. All investments involve the possibility of profit and the risk of loss, including the loss of principal. This document does not constitute an offer to sell or the solicitation of an offer to purchase any security or investment product. All information is current as of the date hereof and is subject to change in the future. | ||||||||||||||||||
|
(1) Performance results are presented on a net-of-fees basis and
reflect the deduction of, among other expenses: management fees,
brokerage commissions, administrative fees, and accrued and/or
crystallized performance fee, if any. Net performance includes the
reinvestment of all dividends, interest, and capital gains.
Depending on the timing of a specific investment, net performance
for an individual investor may vary from the net performance as
stated herein. Performance data and other information contained
herein are estimated and unaudited. Net performance is a
geometrically linked time weighted calculation.
(2) Includes equity and debt securities and derivatives (including swaps and options) relating to equity and debt securities. In the event that there is a change in market cap category with respect to any non-publicly disclosed position, this information is not updated until such position is publicly disclosed. (3) Portfolio composition is reflective of the portfolio as of the date of this report, but is not necessarily indicative of the composition of the portfolio in the future which may be significantly different than that shown here. (4) “Pershing Square Holdings, Ltd. AUM” is the assets under management of Pershing Square Holdings, Ltd. Performance fee crystallized as of the end of the year will be reflected in the following period’s AUM. (5) “Total Strategy AUM” is the aggregate assets under management of Pershing Square, L.P., Pershing Square International, Ltd., Pershing Square II, L.P. and Pershing Square Holdings, Ltd. Redemptions effective as of the end of any period (including redemptions attributable to crystallized performance fee/allocation, if any) will be reflected in the following period’s AUM. (6) “Total Firm AUM” is the aggregate of the Total Strategy AUM and the assets under management of PS V, L.P., PS V International, Ltd. and affiliated entities (collectively, “PSV”), less amounts invested in PSV by the entities listed above (as applicable). |
||||||||||||||||||
|
Note: Each public share in the Company carries at all times one vote
per share. The total voting rights in the Company ("Total Voting
Rights") may vary over time given the capital and voting structure
of the Company. As of June 30, 2015, Total Voting Rights were
498,715,288. There are 240,128,546 Public Shares, 8,500,796
Management Shares and 5,000,000,000 Class B Shares (held by VoteCo)
outstanding (the share classes have 1 vote, 1.0270 votes and 0.0500
votes per share respectively).
Under the Dutch Financial Supervision Act (Wet op het financieel toezicht), anyone who, directly or indirectly, acquires or disposes of shares in the Company and holds voting rights reaching, exceeding or falling below certain thresholds (including 3%, 5% and 10%) of the Total Voting Rights is required to notify the Netherlands Authority for the Financial Markets (Stichting Autoriteit Financële Markten).
In addition, under the Company’s Articles of Incorporation, a person is required to notify the Company of the percentage of the public shares it holds or is deemed to hold (through such person’s direct or indirect holding of financial instruments) if this percentage reaches, exceeds or falls below 3%, 4%, 4.25%, 4.50%, 4.75% or 5% of the total number of outstanding public shares. |
||||||||||||||||||
| As of December 31, 2014, the outstanding Offset Amount to be paid to the investment manager was approximately $102.1M. The “Offset Amount” is an amount equal to the fees and other costs of the placing and admission of the public shares, commissions paid to placement agents and other formation and offering expenses incurred during the private phase of PSH plus accrued interest of 4.25% per annum. As of the date of the placing of the PSH shares, the total Offset Amount was $120M. As of December 31, 2014, the Offset Amount had been reduced by approximately $17.9M net of accrued interest. Once the Offset Amount has been fully paid, PSH’s incentive fee of 16% will be reduced by 20% of the aggregate incentive fees/allocation earned by the investment manager (and its affiliates) on the gains of other private funds managed by the investment manager. Since December 31, 2014, an additional $13.8M net of accrued interest, has been accrued/crystallized towards the Offset Amount. Accrued amounts have not yet been crystallized and are subject to increases/decreases in the future. | ||||||||||||||||||
About Pershing Square Holdings, Ltd.
Pershing Square Holdings, Ltd. is a concentrated, research-intensive, fundamental value investor in the public markets.
View source version on businesswire.com: http://www.businesswire.com/news/home/20150702005893/en/
Contact:
MEDIA
StockWell Communications
Tim Burt, +44
(0)20 7240 2486
Tim.Burt@stockwellgroup.com
Information om Business Wire
Følg pressemeddelelser fra Business Wire
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra Business Wire
AwardFares Launches Intelligent New Alert System for Award Flight Availability5.8.2025 08:00:00 CEST | Press release
AwardFares, the leading search platform for award flights, today launched a major upgrade to its alert system, giving users smarter tools to discover and book award availability faster. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250804412041/en/ AwardFares' Timeline view provides a clear, color-coded visualization of daily award seat availability across different cabin classes, helping users easily spot trends and opportunities for flights. The new system includes two powerful features: Flex Alerts and Live Alerts. Together, they provide both flexibility and precision, helping travelers maximize their points and miles like never before. Flex Alerts are designed for the flexible traveler. Instead of requiring an exact route and date, users can set broad criteria such as "any airport in the US to Europe for an entire month.” AwardFares' AI-powered system intelligently identifies matching availability, focusing not just on
Venture Global Calcasieu Pass Receives Uprate Approval from U.S. Department of Energy5.8.2025 02:02:00 CEST | Press release
Today, Venture Global, Inc. (NYSE: VG) received approval from the U.S. Department of Energy (DOE) for an uprate amendment to its Calcasieu Pass LNG project. The uprate approval increases Calcasieu Pass’ permitted peak liquefaction capacity from 12.0 million tonnes per annum (MTPA) to 12.4 MTPA. “Venture Global thanks its regulators, including DOE, for their efforts in prioritizing and streamlining approvals for critical energy infrastructure projects. These multibillion dollar investments will be key as the United States strengthens global energy security and increases energy trade with our partners around the world,” said Venture Global CEO Mike Sabel. Calcasieu Pass, Venture Global’s first project, reached first LNG production in 2022 and began commercial operations in April 2025. The company’s second facility, Plaquemines LNG, began LNG production in December 2024. Venture Global’s third project, CP2, received DOE export authorization and FERC approval in March 2025 and May 2025, re
Vertex Announces Results from Phase 2 Study of VX-993 for the Treatment of Acute Pain4.8.2025 22:01:00 CEST | Press release
– Treatment with the selective NaV1.8 pain signal inhibitor VX-993 after bunionectomy surgery did not meet the primary endpoint –– Treatment with VX-993 was generally safe and well tolerated, with safety profile similar to placebo arm – Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced topline results from its recently completed Phase 2, randomized, double-blind, placebo-controlled dose-ranging study evaluating the safety and efficacy of its investigational selective NaV1.8 pain signal inhibitor, VX-993, in treating acute pain after bunionectomy surgery. Treatment with VX-993 did not result in a statistically significant improvement on the primary endpoint of the time-weighted Sum of the Pain Intensity Difference from 0 to 48 hours (SPID48) compared to placebo. VX-993 was generally safe and well tolerated. Most adverse events (AEs) were mild to moderate, and there were no serious adverse events (SAEs) related to VX-993. Based on these results, Vertex will not progress
TOURISE Announces Cross-Sector Advisory Board to Champion Bold New Platform Rewriting the Rules of Tourism4.8.2025 20:53:00 CEST | Press release
Leaders from World Travel & Tourism Council (WTTC), Global Sustainable Tourism Council, Amadeus, TikTok, Six Senses, Cirque du Soleil, Turismede Barcelona, Liberty International, Wagonlit Travel, Once Billion Happy, the Saudi Tourism Authority (STA), and the Riyadh School of Tourism and Hospitality at the helm of TOURISE Advisory Board Formation of the Advisory Board reinforces TOURISE’s dedication to driving cross-sector global collaboration Advisory Board shape TOURISE summit agenda, ensuring high-impact global issues such as equity, geographical representation and sectoral diversity are in spotlight TOURISE, the bold new global tourism platform, has announced the members of its cross-sector Advisory Board, a powerhouse of industry titans guiding TOURISE’s strategic direction and shaping the agenda of the inaugural global summit taking place in Riyadh from 11-13 November, 2025. TOURISE is where cross-sector convergence begins, a platform where leaders and visionaries debate, collabor
Concept Medical Announces First Patient Enrollment in MAGICAL-SV IDE Trial, Expanding its Coronary Clinical Program Across the U.S. and Europe4.8.2025 20:38:00 CEST | Press release
Concept Medical Inc., a global pioneer in drug-delivery technologies, announced the enrollment of the first patient in the MAGICAL-SV (MAGIcTouch™ Sirolimus-Coated Balloon for Treatment of Coronary Artery Lesions in Small Vessels) trial, a U.S. Investigational Device Exemption (IDE) study evaluating its MagicTouch™ sirolimus-coated balloon (SCB) for the treatment of small coronary vessels. This first U.S. enrollment follows the FDA’s IDE approval of MagicTouch SCB, marking a major milestone in Concept Medical’s mission to revolutionize coronary artery disease (CAD) treatment and expand its clinical program into the US and Europe. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250804524652/en/ Concept Medical Announces First Patient Enrollment in MAGICAL-SV IDE Study Dr. Samin Sharma enrolled the first patient at New York’s Mount Sinai Hospital, Director of Interventional Cardiology, marking a crucial step in advancing treatm
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.
Besøg vores nyhedsrum